Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That funding will not pay for the salaries and bonuses of mgmt. You know that. Hence, the r/s is inevitable.
Tell you the truth I was more interested in the Liver Disorders Programs for Autoimmune Hepatitis and Liver Transplantation and the mushrooms.
I thought that where their long term future would be best served.
Always thought Covid -19 would be a short fad.
Depends on how this latest deal with the canadian defense dept re treating exposure to nerve agents with buccy develops.
Imo the covid/flu treatment avenue for buccy is a long shot but who knows.
Holding free shares based on how I played the volatility since 2020 so sitting on them long term isnt an issue for me
Use to own this and haven't followed for a while, worth getting back in?
The difference here ""genius"" is that the company will be funded by the Canadian defense entity so your obsessive rs ramblings are moot.
I cannot count the number of times I've heard that excuse with penny stocks. Then when the r/s occurs, everyone is shocked. OMG... how did that happen!
Just give up the rs tourettes gibberish already.
Nobody believes yer bullshite.
Go back to dreaming about that garbage called relief.
RVVTF will run out of money required to pay other bills before this study is complete. Hence, an r/s. They need to start generating revenues (and profits) to avoid an r/s. JMHO
Well doggie, Looky here, what have we? Looks like I was right again. Not only did they file for the patent I suggested ages ago right here, they now have Government funding, in the Middle of peak terrorism season...
$RVVTF News! Revive Therapeutics Enters into Agreement with Defense Research and Development Canada for Evaluating Bucillamine for Nerve Agent Exposure
TORONTO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced that it has entered into an agreement with Defense R&D Canada - Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defense, to evaluate Bucillamine as a potential treatment for nerve agent exposure. The DRDC will fund the research project, which is expected to begin in early Q1-2024.
DRDC is investigating pharmacological compounds that can mitigate nerve agent induced brain injury.
Recent studies have shown that antioxidant compounds such as n-acetylcysteine (“NAC”) could be beneficial in limiting seizure activity and improving the anticonvulsant efficacy of GABA-mediating drugs such as diazepam.
Bucillamine is a significantly more effective antioxidant than NAC and has the potential to provide increased efficacy against seizure activity while limiting the anticoagulant and bleeding event liability observed with NAC. If promising, further studies will be conducted to facilitate Health Canada approval for the use of Bucillamine in nerve agents or organophosphate pesticide poisoning and potentially begin initial studies for efficacy against mild traumatic brain injury caused by concussive or explosive forces.
“We are excited to work with the DRDC in evaluating Bucillamine as a potential therapeutic for nerve agent exposure and validating the novel uses and formulations of Bucillamine for public health medical emergencies, including pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks,” said Michael Frank, CEO of Revive.
med.. based on your excerpts, it looks like you got duped too!
I get looking away for a bit but staying engaged.
Especially if some folks are keeping investment mindset on this. Not everyone keeps a fixed rudder, but can't say it's wrong.
From my view, if it's a new course the waypoints haven't even been set up yet. Revive is square to the wind with block and tackle at the ready but no course map.
No…I don’t think you get it.
I am sure most of us here lost some money but there is still hope. No reason to sell for peanuts when this could at least get back to my initial investment price of .26 cents. GLTA
I get it. I just hope he is bringing us back some dessert. It's not been fun, but I accept the fact that things didn't work out, and I will have to work more, but I am hopeful for a profitable 2024. I'm just not looking at the money so much lately. I agree with the poster who stated that the funding is a good sign. I'll look away for a bit, but for now, it's only a paper loss.
Well it’s quite likely he has been playing golf, eating fine food, and traveling the world with your money.
$RVVTF News! Revive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent Exposure
TORONTO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced that it has entered into an agreement with Defence R&D Canada - Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence, to evaluate Bucillamine as a potential treatment for nerve agent exposure. The DRDC will fund the research project, which is expected to begin in early Q1-2024.
DRDC is investigating pharmacological compounds that can mitigate nerve agent induced brain injury. Recent studies have shown that antioxidant compounds such as n-acetylcysteine (“NAC”) could be beneficial in limiting seizure activity and improving the anticonvulsant efficacy of GABA-mediating drugs such as diazepam. Bucillamine is a significantly more effective antioxidant than NAC and has the potential to provide increased efficacy against seizure activity while limiting the anticoagulant and bleeding event liability observed with NAC. If promising, further studies will be conducted to facilitate Health Canada approval for the use of Bucillamine in nerve agents or organophosphate pesticide poisoning and potentially begin initial studies for efficacy against mild traumatic brain injury caused by concussive or explosive forces.
“We are excited to work with the DRDC in evaluating Bucillamine as a potential therapeutic for nerve agent exposure and validating the novel uses and formulations of Bucillamine for public health medical emergencies, including pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks,” said Michael Frank, CEO of Revive.
About Revive Therapeutics Ltd.
Revive Therapeutics is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Emergency Use Authorization, Orphan Drug, Fast Track, and Breakthrough Therapy designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of public health medical emergencies and rare inflammatory disorders. Revive is also advancing the development of Psilocybin-based therapeutics through various programs. For more information, visit www.ReviveThera.com.
https://finance.yahoo.com/news/revive-therapeutics-enters-agreement-defence-110000524.html
That is a legitimate question. What has Derrick Walsh and the crew been doing for two years?
Ha. Another hoodwink
Wow no way this goes higher on chemical warfare atleast not this month or next
MF doing another hoodwink. Not looking to bottom feed this. Where’s the update on shrooms?
How many times are you going to fall for this bro? MF knows exactly what he's doing and it's working...again. Knock yourself out.
Mar 24, 2021: "The Company is on track to meet its planned enrollment goal for the Study in Q2-2021."
July 15, 2021: "Aim to complete enrollment in Q3-2021 and FDA EUA submission in late-Q3/Q4-2021."
Oct 26, 2021: "Expect to complete enrollment in Q4-2021."
Dec 29, 2021: "Expected to complete enrollment in Q1-2022."
Jan 18, 2022: "On-track to complete enrollment in Q1-2022 and FDA submission thereafter."
Mar 29, 2022: "The Company now expects to complete full enrollment in Q2-2022."
Now we need some chemical warfare right now. All I see is rockets. Israel needs to invade Gaza Hamas send out some chemical warfare and we're in the money. Sad but true
Sorry CW but where have we heard this before?. NAC works but BS is better. At least we get money from gov defense of Canada.
"The DRDC will fund the research project, which is expected to begin in early Q1-2024". This is hugely significant and governments tend to have long pockets. My sense is this is a highly promising update and the markets seems to agree too so far today. Thanks for sharing, CW and hope you are well.
Let's see some official confirmation of this news and then the serious share buying should start again. Remained optimistic that Bucillamine would have other uses and not merely for Covid. Great stuff.
Hungry for anything.The prior data must heavily lean that way.
Hungry for chemical warfare?
I think we are all hungry!
A major problem they have is their 'revenue' is ZERO. I'm not talking about profits. I'm saying they have zero product producing no revenues. Very sad state of affairs. An r/s is inevitable in order to pay the insider salaries and bonuses.
Correct me if I’m wrong but I think the earnings report will be out later this month. Perhaps we will get a glimpse of their cash position, but I see no other way out except an r/s followed by share dilution. The problem is you need buyers in that case. Who in their right mind is going to buy this stock through an offering now? If I recall they had trouble finding buyers in the last offering and the company is in much worse shape now.
No comments from EcoMike to grab more cheapies? Hope you bagholders who continued to support that fraud finally understand that you were had.
Gatorca, I was lucky to have exited this around .40 with a very small loss. I didn't like MF after seeing him in an interview. Not professional IMO (pretty sleezy). The guy couldn't even sit up in a chair right, and his PR's appeared to obsessed with shrooms (rather than EUA for Bucillamine. Also, he dragged his feet when the FDA gave the red light by taking months to get the trial off the ground. The guy was not prepared at all. So I got out.
On the other hand, I lost a good chuck of change on RLFTF (small Swiss based biotech). RLFTF had a lot of pumping by the doctor doing the trial and suckered me in. They too were seeking EUA for covid. In the end the FDA essentially rejected their drug.
I've concluded that it is a very low probability trade to think that the FDA will approve a drug from a small foreign country..... and that includes Canada. IMO, MF has run out of tricks, so he has invented another one to lure in new investors. Their only real source of cash inflow is dilution, so I'm reasonably sure that we'll see a devastating r/s in 2024 (2025 at the latest). But I will continue to watch this stock in case there is a new, major turn of events. But I have very little faith now.
Penny I sold most but not all of this investment. I like most have no idea wtf Mf is trying now . That's why I said just waiting for news Dec, not like I'm holding my breath it will be Good. Why did they String us long real investors along for maybe 18 months like they had decent data for symptoms when they Knew or should of that the Trial was only taking the Very Basics for symptoms(or bad trial set up) and Why not at least give Biomedical_trader a chance at the data which he must of offered to do for free as you can see in his comment here and about how they should of unblinded the data and not lead us along for the year or so, and also I wonder if that is legal for a company to do that lol.
https://www.reddit.com/r/RVVTF/comments/15nh2p3/the_fat_lady_hasnt_sang_yet/jyp41su/?context=3
Hello CW, I moved on but still on ihub, but i took a $120k hit. It's my own fault but I figured instead of holding for several years more, I'll find somewhere else to put what little I salvaged and make something. Wishing you well and all the other long time holders!
Oh for sure! Sometime in 2024 most likely they will need to do an r/s. It's SOP in penny stock land.
stock barely reacted to the news. Not bottom fishing this. Pretty soon they will need to dilute again I expect they continue to burn their cash with no revenue opportunities in sight
What’s up with the shrooms business???
Unfortunately it appears like the same, old routine all over again. We’ll see who learned their lesson and who didn’t. You’re right it’s years away from anything and this company has no money. What a combo.
Wouldn't the start of clinical trials in 2024 equate to starting at ground zero (Phase 1 FDA)? If so, unfortunately that initiative is many years away from fruitation. The EUA piece of that PR is just a pump IMO.
The News.. Under an agreement with the University of Waterloo, formulation development is ongoing and aims to be completed by the end of December 2023. So that's what I meant CW. etc. by news not until Dec....that I'm waiting on lol anyway.
https://www.globenewswire.com/news-release/2023/10/11/2758381/0/en/Revive-Therapeutics-Provides-Update-of-Novel-Bucillamine-Formulation-Development.html
Revive Therapeutics Provides Update of Novel Bucillamine. $RVVTF https://t.co/miWvtn0rVD
— Rex Wiggins (@RexWiggins12) October 11, 2023
Yea Cw that other
investment went back down to about my average there lol but with the great dd there I think there is a much better chance of some good things with their patents etc. will happen by Dec. than news about bucy in which I think was going to be by Dec also, if I even remember right lol. If you sold that and u made some back that is good though . But it was really PB that first post it here One thing ? I do not understand is why rvvtf management would not even let Biomedical_trader try to tweak the bucy data for Free....
Ps. anyway take another look at Pb and some others dd there...
pps. still holding some here, maybe buy more depending on any news dec lol. and if other investment goes good.
Hello ladies & gentlemen just checking in see whats going on and as I see not much.
Trying to keep the faith,along with hope,but still feeling the pain. Just for old times sake
lets give a CW classic !!!! LET`S GO !!!!!
Lurking in the shadows CW.
All the best to you.
Hey bud- I've, arguably, taken the biggest hit of them all. I haven't averaged down because I am not sure where we are going. I made some money back thanks to Gator, (thanks, Gator btw) but I just don't know what to do with this one. I wait for a miracle as each week as MF takes his large salary, and I don't even know what he is working on at this time. I hold with just a slight hope of ever getting back my money. I only check three times a day for a stock price which is down from 75 checks as one time. I read everything here, but I haven't seen much to comment on lately. It's just not exciting to look here when I see red every day.
I just came off a four day just trial and have a new appreciation of our judicial system. It's fascinating. I hope one day to be active on here again, but it's up to MF to put some new energy into this stock and revive me from my doldrums.
ps. Regards to all the boys if they still are around. Blue, Rubber, All in, etc.
Tomorrow is Buy time for me again here frankly. You alive & well, CW? Your presence is missed for sure man.
I can live with this. I mean I agree with all of it for the most part. I have been an actual investor for 3 years. Yes I played the volatility well but still hold a small amount of shares. You seem to understand the risks here but many on this board either did not, or they did and overhyped the stock, ie bull. I'm a boomer (late stage) and don't do well with bull. How about an honest conversation? So when I ask if somebody can show me just one PR that proved true or came to fruition, I'm simply asking for some honesty. Is it asking too much? Thank you for an honest reply to my post.
The core Pr's were based on the drug achieving statsig which would/could have enabled it being given some type of approval by the fda.
The fact that this didnt happen has zero to do with your asinine assertion of them not coming to fruition.......well funded biotech drugs fail to deliver all the time so theres nothing special here when it comes to revive.
Like ive previously stated, based on hindsight, we now know that the original ep's were doomed to failure from day one due to the aggressive mutation of the virus to less virulent strains and as such "WE", ie actual investors, are where we are at the moment.
Its a valid argument that its due to mf's lack of foresight and forcefulness to expedite the trial to completion, but then again absolutely nothing was assured per buccy receiving eua for covid.
For many this was a hugely -ve outcome due to the precipitous pps drop since past highs, whereas for others it was neither here nor there because of smart trading all during the volatility.
All you have to do is show just one PR that was proven true or came to fruition. Wouldn’t that be an informed opinion and/or valid exchange of ideas? I’m open to it.
Only beneficial to engage with persons whose core intent is to present an informed opinion and-or exchange valid ideas.
These numpts do neither but rather only seek to denigrate and hurl outlandish commentary that when closely examined do not stand up to close scrutiny.
Would help their cause greatly if the most vociferous of the lot were ever actual investors rather than silly agitators.
Yes absolutely UNHINGED!!!
Quote: "Yes the deception is real. I challenge any and all pumpers to show us just one PR that proved true or came to fruition. Come on enablers of The Big Lie, stand up and show us where MF and Revive have ever succeeded. You talk the talk, now walk the walk. Bring it!"
#unhingedarseclown
Followers
|
339
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
36630
|
Created
|
02/23/17
|
Type
|
Free
|
Moderators Classic Warrior |
Scientific Rationale of Bucillamine
Preclinical and clinical studies have demonstrated that reactive oxygen species contribute to the destruction and programmed cell death of pulmonary epithelial cells.1 N-acetyl-cysteine (NAC) has been shown to significantly attenuate clinical symptoms in respiratory viral infections in animals and humans, primarily via donation of thiols to restore antioxidant and to reduce the activity of cellular glutathione 2,3,4,5. Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine) has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years. Bucillamine, a cysteine derivative with two thiol groups, has been shown to be 16 times more potent as a thiol donor in vivo than NAC 6. The drug is non-toxic with high cellular permeability. The basis of the clinical study will analyze if Bucillamine has the potential, via restoration of glutathione activity and other anti-inflammatory activity, to lessen the negative consequences of SARS-CoV2 infection in the lungs.
| Psilocin Pharma Corp. has developed production solutions for the active compound Psilocybin. Our process encompassed with our intellectual property cover methods of production of Psilocybin based formulations. Psilocin Pharma Corp’s range of products have been engineered to work synergistically with the body's own natural pathways of absorption while offering a contemporary approach to consumption. Psilocin Pharma also has strong relationships with specific lab partners in certain areas like Brazil, where these formulations are legally approved and plan to sell products in these jurisdictions. | |
| |
Mental Health (Depression, PTSD & Anxiety)
|
Supplements for Brain Health & Cognitive Enhancement
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |